Description: This session will look into life insurers’ anticipated business impacts as a result of the implementation of the new accounting standard for insurance contracts, IFRS 17. What will be the financial impact as of day one as a result of transition? How will embedded value for common life insurance products change? How will costs of reinsurance be affected? Will products have to be re-designed and/or re-priced? IFRS 17 may have more ramifications into the way insurers are doing business than we have anticipated so far. While we are working on the implementation of this new standard, we should not lose sight of the business impacts that will follow. At the conclusion of the session, attendees will be able to: Understand key impacts of the transition to IFRS 17; See illustrative examples of the impact on embedded value; and Understand key impacts on product design and pricing Country Relevance: US and Canada

Description: 2016 marks the 60th anniversary of the Canadian Reinsurance Conference. This one day industry meeting hosting delegates from North America and beyond will be held in Toronto on April 13, 2016 under the theme "ReDefining Leadership".

Description: Discussion of solvency problems and the actuary's role in addressing them in the life insurance industry.

Description: The presenters will explore the current state of the North American mortality baseline and long-term improvement assumptions and determine what we can learn from the UK's approach. They will share research done by the Society of Actuaries and other organizations to describe how to build a better model, plus show the impact socio-economics and other factors have on longevity expectations. The presenters will offer suggestions for how U.S. and Canadian pension plan and insurance actuaries--and the industry itself--can best use this research to develop a better model for the risk management of pension plans and group annuities

Description: Pricing longevity swap reinsurance transactions consists of a number of different actuarial tasks, each of which hides potential pitfalls. The article outlines the pricing process, which includes a detailed analysis of current mortality experience of the portfolio to be transferred, choice and calibration of an appropriate model for mortality improvement trends and the calculation of a risk margin which reflects the uncertainty associated with the pricing best-estimate, which includes mis-estimation risk, model risk, longevity basis risk and stochastic uncertainty.